- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. have partnered to distribute Neuraceq® from PharmaLogic’s Denver site.
- The first doses were made available on August 20th, 2024, expanding access to this FDA-approved imaging agent for Alzheimer’s diagnosis.
Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. have announced a strategic partnership and licensing agreement to distribute Neuraceq® from PharmaLogic’s radiopharmaceutical manufacturing site near Denver, Colorado. The collaboration aims to enhance the availability of this FDA-approved imaging agent used in the detection of beta-amyloid plaques, which are indicative of Alzheimer’s disease and other cognitive impairments.
Neuraceq®, utilised in both clinical settings and research, plays a critical role in the diagnosis of Alzheimer’s disease by identifying beta-amyloid plaques in the brain. This imaging agent is also instrumental in assessing patients for treatment eligibility with anti-amyloid drugs and for enrollment in clinical trials focused on neurodegenerative diseases. The first doses from the Denver facility became available on August 20th, 2024.
“By partnering with PharmaLogic and offering Neuraceq® in Denver, Life Molecular Imaging is excited to expand access of Neuraceq® for the detection of beta-amyloid plaques in the brain,” said Ludger Dinkelborg, Ph.D., Managing Director at LMI. He added that this expansion benefits not only physicians and patients but also LMI’s pharmaceutical partners in both routine clinical and research applications.
Steve Chilinski, CEO of PharmaLogic, commented on the collaboration, stating, “Expanding patient access to clinically impactful radiopharmaceuticals is a core component of our mission. By partnering with Life Molecular Imaging in Denver, patients in the greater Rocky Mountain region will have even greater access to a new wave of disease-targeting diagnostic radiopharmaceuticals.”
Overview of outsourcing trends 
